IP Group

IP Group, founded in 2001 and based in London, is a venture capital investment firm focused on the commercialization of intellectual property from research-intensive institutions. The firm specializes in providing financial, strategic, and commercial expertise to facilitate the development of businesses in sectors such as clean technology, life sciences, and deep technology. By leveraging its extensive industry knowledge and financial acumen, IP Group effectively identifies and manages suitable intellectual property for commercialization, helping to create value for shareholders and partners. The firm has established a strong track record of delivering positive results through its strategic investments and partnerships, thereby enhancing the potential of innovative companies in its portfolio.

Alan Aubrey

CEO, Executive Director and Member of the Board of Directors

Greg Smith

CEO

Lee Thornton

Partner, Technology

Robert Trezona

Partner and Head of Cleantech

Samuel Williams Ph.D

Managing Partner, Life Sciences

253 past transactions

AccelerComm

Series B in 2023
AccelerComm Ltd is a semiconductor IP-core company based in Southampton, United Kingdom, specializing in Forward Error Correction (FEC) solutions for wireless communications. Established in 2016, the company develops innovative error correction decoders designed for various markets, including mobile handsets, base stations, and satellite communications. Its product offerings include Polar, Turbo Decoder, and LDPC encoding/decoding chains, which are compliant with 3GPP standards. AccelerComm's technology addresses performance bottlenecks in next-generation wireless communication by enhancing the error correction processes necessary to mitigate the impacts of noise, interference, and poor signal strength. By providing cost-effective and high-performance solutions, AccelerComm enables clients to optimize their digital communication systems.
Intrinsic Semiconductor Technologies is established to developed silicon-oxide based RRAM technologies. Intrinsic's technology is fully air stable and inherently CMOS compatible. Intrinsic's core technology can be configured as non-volatile memory, multilevel memory, hardware acceleration for Machine Learning, and neuromorphic devices.

AMSL Aero

Series B in 2022
AMSL Aero Pty Ltd designs and manufactures electric plane. VERTIIA, an electric aircraft allows urban and regional passenger transportation, cargo transportation, and aeromedical transportation. AMSL Aero Pty Ltd was incorporated in 2017 and is based in Stanmore, Australia.

Abliva AB

Post in 2022
Abliva AB is a biotechnology company based in Lund, Sweden, that specializes in the research and development of mitochondrial medicine. The company is advancing several drug candidates, including KL1333, which is in Phase I clinical trials for chronic treatment of primary mitochondrial diseases, and NV354, which is being prepared for clinical trials targeting Complex I deficiency in mitochondrial diseases. Additionally, Abliva is developing NeuroSTAT for the treatment of traumatic brain injuries and is currently engaged in a Phase II/III adaptive clinical study for this indication. The company also has a cyclophilin-D-inhibiting cyclosporine, CicloMulsion®, undergoing a Phase III clinical study for reperfusion injury. Abliva collaborates with various institutions and organizations, including academic hospitals and pharmaceutical companies, to enhance its research and development efforts. Founded in 2000 and previously known as NeuroVive Pharmaceutical AB, the company rebranded to Abliva AB in May 2020.

MoA Technology

Series B in 2022
MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that specializes in developing sustainable agricultural technologies. Founded in 2017 as a spin-out from the University of Oxford, the company focuses on discovering new herbicide chemistries with innovative modes of action derived from both natural and synthetic sources. By utilizing a proprietary in vivo plant-based genomic process, MoA Technology identifies specific target proteins linked to these new modes of action, thus providing farmers with a diverse range of effective weed control solutions. The company's approach aims to enhance food production while promoting sustainable crop systems.

Slamcore

Series A in 2022
Slamcore Limited specializes in developing simultaneous localization and mapping (SLAM) solutions for applications in augmented and virtual reality, robotics, and autonomous vehicles. Founded in 2016 and based in London, the company focuses on making commercial-grade spatial intelligence accessible. Its advanced SLAM software enables robots and drones to effectively navigate and comprehend their environment, utilizing methods such as Visual SLAM, sensor fusion, and Event Camera SLAM. These technologies allow for real-time processing and integration of data from various sensors, enhancing capabilities in areas like motion estimation and panorama reconstruction. Slamcore collaborates with partners to optimize the interplay between software and hardware, ensuring a balanced approach to performance and cost-effectiveness. By providing robust SLAM algorithms, the company aims to transform spatial AI into practical solutions for various industries, ultimately facilitating the integration of robots into everyday life.

Ankere Therapeutics

Seed Round in 2022
Ankere is striving to develop transformative therapies based on excellent science that will enable people to live long and healthy lives.

GripAble

Series A in 2022
Gripable is develops simple digital therapy tools, combining them with mobile games, motivating physically impaired patients. GripAble began during our research with stroke patients struggling to use their hands for simple activities. Everyday tasks - getting dressed in the morning, holding a glass of water - are a huge frustration for them. This is the reality for over 500 million people around the world suffering with impaired arm mobility. These patients need, and want, more therapy. GripAble's first product is a highly sensitive, portable hand-grip that connects wirelessly with a mobile-based app, allowing patients to play our fun therapy games. It is designed for low-cost, easy-access assessment and therapy of hand and arm disability, providing increased engagement and allowing for self-training in hospitals and at home.

Kynos Therapeutics

Seed Round in 2022
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.

Aptatek Biosciences

Seed Round in 2022
Aptatek Biosciences Inc is a Princeton, New Jersey-based company that develops portable disease management devices specifically for individuals with Phenylketonuria (PKU). Their innovative products utilize sensor technology to monitor phenylalanine levels in real-time, allowing for immediate blood analysis and reporting. These Bluetooth-enabled devices facilitate the detection of small molecules and biomarkers, enabling patients to make timely dietary adjustments to maintain their phenylalanine levels within clinical target ranges. By providing healthcare providers with tools to enhance patient compliance and overall wellness, Aptatek Biosciences aims to improve the quality of life for those affected by PKU.

Vytal

Series A in 2022
VYTAL Global GmbH, founded in 2019 and based in Cologne, Germany, operates a digital reusable system aimed at reducing single-use packaging waste in the food industry. The company offers an application that enables consumers to select reusable bowls instead of disposable ones when ordering take-away or delivery food. Users can borrow bowls by displaying a QR code from the app or their membership card, and return them at any partner location or designated return boxes. VYTAL serves a wide range of stakeholders, including consumers, restaurants, canteens, caterers, and municipalities. In response to the significant environmental impact of single-use packaging, which generates substantial waste and greenhouse gas emissions, VYTAL positions itself as a sustainable alternative, promoting a circular economy within the growing market for convenience and delivery food.

Alimetry

Series A in 2022
Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.

Barocal

Seed Round in 2022
Barocal is a Zero-carbon refrigeration.

First Light Fusion

Series C in 2022
First Light Fusion Limited is a company focused on developing advanced implosion processes for electricity generation. Founded in July 2011 as a spin-out from the University of Oxford, the company initially operated under the name Oxyntix Ltd. until a rebranding in June 2014. The founders, Professor Yiannis Ventikos and Dr. Nicholas Hawker, have backgrounds in mechanical engineering and academia. Based in Begbroke, United Kingdom, First Light Fusion employs a team of engineers and physicists and maintains collaborations with several prestigious academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company's mission is to innovate in the field of energy generation through cutting-edge research and technology.

Bramble Energy

Series B in 2022
Bramble Energy Ltd. is a London-based company that specializes in the design, development, and manufacture of printed circuit board fuel cells (PCBFCs). Leveraging its expertise in the high-volume printed circuit board industry, the company produces a range of fuel cell products, including 20 W, 500 W, and 5 kW PCBFC stacks, as well as custom-designed solutions. Bramble Energy aims to supply gigawatts of fuel cell hardware, positioning itself as a leader in the energy technology sector. Its innovative approach caters to various applications across the stationary, portable, automotive, and mobility sectors. Founded in 2015, Bramble Energy is focused on delivering high-performance and cost-effective fuel cell solutions.

Microbiotica

Series B in 2022
Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.

Diffblue

Seed Round in 2022
Diffblue is changing the way software is developed using Artificial Intelligence (AI). Diffblue Cover, the company’s first product, automatically generates tests for Java code to enable development teams to deliver higher quality software, faster. Diffblue’s technology is developed by its team of leading experts in AI, software verification and synthesis, and customers include Goldman Sachs and Amazon Web Services. Diffblue is backed by Oxford University, Oxford Sciences Innovation and Goldman Sachs and is headquartered in Oxford, UK.

Canopus

Series A in 2021
Canopus Networks Pty Ltd is an Australian company founded in 2018, specializing in software-defined networking and artificial intelligence technologies. The company focuses on providing solutions for internet service providers to effectively manage and isolate streaming video and gaming traffic, ensuring a consistent user experience during network congestion. Canopus develops a platform that offers encryption-proof network observability, enabling high-speed analysis of network flows. This platform is essential for telecommunications operators who need to monitor application and network performance amidst increasing data rates and encryption challenges. Canopus serves various sectors, including fixed operators, gaming, 5G mobile operators, live video streaming, business applications, security, and government entities.

Navenio

Venture Round in 2021
Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice. The company was founded in 2015 and is headquartered in Oxford, England.

ieso

Series B in 2021
Ieso Digital Health Ltd. specializes in providing online evidence-based cognitive behavioral therapy (CBT) to individuals facing various mental health challenges, including anxiety and depression. The company's unique online service facilitates real-time communication between accredited therapists and patients through a secure virtual environment, where sessions are conducted via text. This approach not only mirrors traditional face-to-face interactions but also offers greater convenience for users. Ieso began its operations in the UK in 2000 and has since expanded into the US market, collaborating with Medicaid and commercial health plans to enhance access to mental health services. The company’s therapy model has demonstrated effectiveness, requiring fewer sessions to achieve recovery and showing improved outcomes compared to conventional therapy methods. Ieso serves a diverse clientele, including health providers, private individuals, and businesses, and is recognized for its rapid growth in the digital health sector.

Teya

Series C in 2021
SaltPay is a FinTech company dedicated to building a better future for merchants by servicing them through payment and management tools. Focused on efficiency, technology, and people, they give merchants the help they need to grow.

Arkivum

Private Equity Round in 2021
Arkivum delivers software, services and domain expertise for long term data management and digital preservation globally. We serve organisations around the world in data intensive and regulated markets. We make your long term data secure, accessible and usable for as long as you need it, providing assurance your data is where you need it, when you need it. Our domain expertise means we can guarantee 100% data integrity and best practice guidance for dealing with new compliance requirements as they are introduced. Our vendor neutral technology and no data lock-in means your data lives where you want it to and you own your data at all times. Arkivum delivers complete confidence in preserving, meeting complex compliance and regulatory requirements and creating business value from your data. Bringing your archived data to life.

MOBILion Systems

Series C in 2021
Mobilion Systems, Inc. is a biotechnology company based in Chadds Ford, Pennsylvania, that specializes in advanced ion mobility separation technology known as structures for lossless ion manipulation (SLIM). Founded in 2015, the company focuses on identifying and analyzing difficult-to-detect molecules, particularly those relevant to biologic therapeutics and disease diagnostics. Mobilion's innovative SLIM technology allows for the separation and detection of clinically significant biomolecules that conventional instruments struggle to identify. By providing enhanced sensitivity, resolution, and throughput, Mobilion's analytical instruments support the development of improved therapeutics and enable earlier disease detection, ultimately aiming to address diseases at their core rather than merely treating symptoms.

Pulmocide

Series C in 2021
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Oxford Nanopore Technologies

Venture Round in 2021
Oxford Nanopore Technologies Limited specializes in the development and commercialization of nanopore-based electronic systems for the analysis of single molecules, particularly in the fields of DNA and RNA sequencing. The company offers a range of products, including the portable MinION device for molecular analysis, the benchtop PromethION for large-scale sequencing projects, and the GridION system suitable for various molecular sensing applications. Their technology supports diverse scientific research areas such as genomics, cancer studies, microbiology, and environmental research, with applications extending to healthcare, agriculture, and food safety. The Flongle device caters to on-demand sequencing needs, while the MinIT accessory enhances the functionality of their sequencing devices. Oxford Nanopore’s innovative technology emphasizes accessibility and ease of use, with rapid library preparation and automated processes. Founded in 2005 and headquartered in Oxford, United Kingdom, the company operates additional offices worldwide, enabling its products to be utilized in over 80 countries.
Intrinsic Semiconductor Technologies is established to developed silicon-oxide based RRAM technologies. Intrinsic's technology is fully air stable and inherently CMOS compatible. Intrinsic's core technology can be configured as non-volatile memory, multilevel memory, hardware acceleration for Machine Learning, and neuromorphic devices.

Oxular

Venture Round in 2021
Precision Ocular Metrology is a medical device startup dedicated to revolutionizing the way we measure ocular surface topography. Standard Placido disk slope measurements are great for optical power measurements on the central regions of the cornea but provide poor elevation topography, making them poor choices for specialty lens fitting. Our sMap3D topographer addresses this problem by providing direct anterior surface elevation measurements, letting you map the complete three-dimensional eye surface with an unprecedented 10 um precision.

Carisma Therapeutics

Series B in 2021
Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

C-capture

Venture Round in 2021
C-Capture Ltd utilise their extensive knowledge of CO2 (carbon dioxide) based chemistry and engineering, to develop a bottom-up approach to designing solvent systems for the removal of CO2 from gas streams. CO2 is considered to be a ‘greenhouse gas’ and its release into the atmosphere is one of the leading contributors to global warming.

Carisma Therapeutics

Series B in 2021
Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

Oxa

Series B in 2021
Oxbotica is developing the next generation of autonomous vehicles - creating the software that makes them go. Using the latest in computer vision and machine learning, their systems learn from their environment and share experiences with each other, so that they're getting smarter all the time. The system uses a complement of sensors and algorithms to identify and track pedestrians, cars and other obstacles in the environment.

AudioScenic

Series A in 2020
AudioScenic Limited, established in 2017 and headquartered in Southampton, United Kingdom, specializes in 3D audio technology that enhances the listening experience across various sectors, including cinema, gaming, virtual reality, and automotive industries. The company utilizes advanced head-tracking and small arrays of speakers to deliver controlled sound beams directly to the listener's ears, creating a virtual headphone effect. This technology allows for a personalized and immersive audio experience without the need for traditional headphones or extensive loudspeaker setups. By simulating sounds positioned in 3D space, AudioScenic's solutions eliminate the limitations of conventional audio systems, providing a natural and authentic sound environment. The company's proprietary Virtua 3D Engine facilitates the implementation of its audio technology across different platforms, ensuring compatibility and optimization for various applications. AudioScenic collaborates closely with partners and customers to develop tailored acoustic designs for a range of products, enhancing the overall audio experience in both private and public settings.

Alimetry

Seed Round in 2020
Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.

AccelerComm

Series A in 2020
AccelerComm Ltd is a semiconductor IP-core company based in Southampton, United Kingdom, specializing in Forward Error Correction (FEC) solutions for wireless communications. Established in 2016, the company develops innovative error correction decoders designed for various markets, including mobile handsets, base stations, and satellite communications. Its product offerings include Polar, Turbo Decoder, and LDPC encoding/decoding chains, which are compliant with 3GPP standards. AccelerComm's technology addresses performance bottlenecks in next-generation wireless communication by enhancing the error correction processes necessary to mitigate the impacts of noise, interference, and poor signal strength. By providing cost-effective and high-performance solutions, AccelerComm enables clients to optimize their digital communication systems.

MOBILion Systems

Series B in 2020
Mobilion Systems, Inc. is a biotechnology company based in Chadds Ford, Pennsylvania, that specializes in advanced ion mobility separation technology known as structures for lossless ion manipulation (SLIM). Founded in 2015, the company focuses on identifying and analyzing difficult-to-detect molecules, particularly those relevant to biologic therapeutics and disease diagnostics. Mobilion's innovative SLIM technology allows for the separation and detection of clinically significant biomolecules that conventional instruments struggle to identify. By providing enhanced sensitivity, resolution, and throughput, Mobilion's analytical instruments support the development of improved therapeutics and enable earlier disease detection, ultimately aiming to address diseases at their core rather than merely treating symptoms.

Bramble Energy

Series A in 2020
Bramble Energy Ltd. is a London-based company that specializes in the design, development, and manufacture of printed circuit board fuel cells (PCBFCs). Leveraging its expertise in the high-volume printed circuit board industry, the company produces a range of fuel cell products, including 20 W, 500 W, and 5 kW PCBFC stacks, as well as custom-designed solutions. Bramble Energy aims to supply gigawatts of fuel cell hardware, positioning itself as a leader in the energy technology sector. Its innovative approach caters to various applications across the stationary, portable, automotive, and mobility sectors. Founded in 2015, Bramble Energy is focused on delivering high-performance and cost-effective fuel cell solutions.

Mission Therapeutics

Venture Round in 2020
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.

Oxford Ionics

Seed Round in 2020
Developer of advanced quantum computing systems designed to create chips for high-performance applications. The company's platform features trapped-ion technology that enables scalability and efficiency, utilizing standard semiconductor fabrication methods to produce quantum chips globally, enabling clients to facilitate significant advancements in the quantum computing market and providing enhanced computational capabilities for complex problem-solving.

IBEX Innovations

Venture Round in 2020
IBEX Innovations Limited specializes in the development and commercialization of advanced X-ray detector technology that enhances material analysis capabilities. The company's proprietary multi absorption plate (MAP) technology integrates with standard X-ray detectors, enabling high sensitivity material classification while maintaining key performance characteristics such as speed and spatial resolution. This innovative solution is applicable across various sectors, including medical imaging, electronics, food safety, and security. Founded in 2010 by Dr. Gary Gibson and based in Sedgefield, United Kingdom, IBEX has rapidly evolved from its initial concept to a recognized provider of engineered solutions. The company collaborates with academic and healthcare institutions, including Durham University and NHS trusts, to validate and advance its technology. IBEX Innovations has received support from venture capital firms and grants from InnovateUK and the European Commission to foster its growth and development.

Navenio

Series A in 2020
Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice. The company was founded in 2015 and is headquartered in Oxford, England.

Quantum Motion

Series A in 2020
Quantum Motion Technologies Limited is focused on developing a universal quantum computer utilizing silicon-based technology and CMOS-compatible processes. Founded in 2017 and based in Leeds, United Kingdom, the company aims to create scalable quantum computing architectures that address issues such as fault tolerance and qubit redundancy. Its technology is designed to enhance qubit density, allowing for the construction of large-scale quantum systems capable of solving complex problems in various fields, including chemistry, medicine, and artificial intelligence. By leveraging advanced architectural approaches, Quantum Motion Technologies seeks to advance the quantum technology sector and provide solutions that reduce errors and overcome critical challenges in quantum information processing.

RFC Power

Seed Round in 2020
RFC Power Ltd, founded in 2017 and based in London, specializes in the development of low-cost hybrid flow battery systems designed for renewable energy storage. The company focuses on innovative redox flow battery chemistry that utilizes non-toxic and abundant materials, combining optimized cell architecture with hydrogen manganese chemistry. This unique approach allows RFC Power's batteries to deliver reliable energy storage with minimal capacity loss, making them suitable for various applications. By leveraging concepts from fuel cells, RFC Power aims to provide simple and safe solutions for energy storage, ensuring that renewable energy can be efficiently stored and used when needed.

Instrumems

Seed Round in 2020
Instrumems Inc. develops nano-wire sensors, a sensing platform that allows measuring of temperature, velocity, and humidity. The company was founded in 2016 and is based in Los Altos, California.

Mixergy

Series A in 2019
Mixergy Ltd, founded in 2014 and based in Cassington, United Kingdom, specializes in the development of energy storage solutions, particularly hot water tanks. The company provides a cost-effective means to enhance energy efficiency and support renewable energy generation by improving grid balancing. Mixergy's innovative tanks are designed to optimize the use of solar photovoltaic systems and heat pumps, thereby enabling better energy utilization and contributing to sustainable energy practices.

MOBILion Systems

Series A in 2019
Mobilion Systems, Inc. is a biotechnology company based in Chadds Ford, Pennsylvania, that specializes in advanced ion mobility separation technology known as structures for lossless ion manipulation (SLIM). Founded in 2015, the company focuses on identifying and analyzing difficult-to-detect molecules, particularly those relevant to biologic therapeutics and disease diagnostics. Mobilion's innovative SLIM technology allows for the separation and detection of clinically significant biomolecules that conventional instruments struggle to identify. By providing enhanced sensitivity, resolution, and throughput, Mobilion's analytical instruments support the development of improved therapeutics and enable earlier disease detection, ultimately aiming to address diseases at their core rather than merely treating symptoms.

Kira Biotech

Series A in 2019
Kira Biotech Pty Ltd is an Australian biotechnology company focused on developing innovative immunomodulatory compounds for treating immune system disorders, including rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes. Established in 2017 and based in Brisbane, Kira Biotech is advancing its lead candidate, KB312, a first-in-class selective monoclonal antibody designed to target activated immune cells. This approach aims to restore immune system balance by inducing tolerance. The company has secured venture capital funding and is currently progressing KB312 through preclinical development and phase 1 clinical trials, guided by a team of experts in drug development, including prominent US-based rheumatologist and immunologist Dr. Dan Baker.

Inflowmatix

Series B in 2019
Inflowmatix Limited is a technology company based in London that specializes in designing and implementing electronic systems for water utilities globally. Founded in 2015 as a spin-out from Imperial College London's InfraSense Labs, Inflowmatix focuses on providing water flow and system health analytics to enhance the operation of water supply networks. Their innovative solutions continuously monitor and analyze fluid dynamics, enabling operators to optimize performance, manage leakage, and improve energy efficiency. By capturing high-frequency pressure data and applying advanced modeling techniques, Inflowmatix helps water companies gain insights into their operations, extend the life of aging infrastructure, and address challenges posed by increasing population demands and climate change. The company’s technology aims to deliver compelling returns on investment while supporting water utilities in maintaining high-quality service within cost constraints.

CareAlign

Pre Seed Round in 2019
TrekIT provides clinicians with an intuitive, patient-centric task management tool to track, manage and coordinate clinical care. Easily assign, date and time tasks, categorize them for when they are due, view cleared tasks and more.

Growave.ag

Seed Round in 2019
Growave is an Agtech startup company offering herbicide free weed management.

WaveOptics

Series C in 2019
WaveOptics, Ltd. specializes in the design and manufacture of augmented reality display technology, focusing on optical waveguides for wearable devices. The company offers features such as binocular displays, high field-of-view, and full RGB color in lightweight designs. Founded in 2014 and based in Abingdon-on-Thames, United Kingdom, WaveOptics has established strategic partnerships with companies like Compal, Wistron, and Plessey to enhance its product offerings. The company aims to be a pivotal supplier of optical components for the growing augmented reality market.

Exyn

Series A in 2019
Exyn Technologies, Inc. is a Philadelphia-based company specializing in autonomous aerial robotics, having emerged from the GRASP Laboratory at the University of Pennsylvania. Founded in 2014, the company has developed exynAI, a modular software system that enables pilot-less flights for drones in complex commercial settings. This technology leverages multiple redundant sensors and advanced mapping techniques to facilitate obstacle avoidance and autonomous flight planning, allowing for applications such as underground inspections, inventory management, and construction documentation. Exyn's drones operate without human control or GPS, making them particularly suited for navigating challenging environments and automating hazardous tasks.

Azuri Technologies

Corporate Round in 2019
Azuri Technologies Ltd. develops, manufactures, and installs solar power products for off-grid emerging markets in Africa and the United Kingdom. The company offers AzuriTV, a solar-powered television; Indigo, a pay-as-you-go system that enables solar electricity to be delivered as a service using scratch cards for payment; Azuri Quad, a solar home system that provides household lighting, including LED lights, rechargeable radio and torch, and mobile phone charging; and PayGo, a solar home system that delivers clean energy to rural households living without electricity. The company was founded in 2012 and is based in Cambridge, United Kingdom with distribution networks in Kenya, Uganda, South Sudan, Zambia, and South Africa.

IBEX Innovations

Venture Round in 2019
IBEX Innovations Limited specializes in the development and commercialization of advanced X-ray detector technology that enhances material analysis capabilities. The company's proprietary multi absorption plate (MAP) technology integrates with standard X-ray detectors, enabling high sensitivity material classification while maintaining key performance characteristics such as speed and spatial resolution. This innovative solution is applicable across various sectors, including medical imaging, electronics, food safety, and security. Founded in 2010 by Dr. Gary Gibson and based in Sedgefield, United Kingdom, IBEX has rapidly evolved from its initial concept to a recognized provider of engineered solutions. The company collaborates with academic and healthcare institutions, including Durham University and NHS trusts, to validate and advance its technology. IBEX Innovations has received support from venture capital firms and grants from InnovateUK and the European Commission to foster its growth and development.

STORM Therapeutics

Series A in 2019
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.

Aqdot

Series B in 2019
Aqdot Limited, founded in 2012 and located in Cambridge, United Kingdom, specializes in the manufacturing of smart microcapsules with customizable properties tailored for various industries. The company has developed a unique one-step shrink-wrap approach that combines emulsion technology and supramolecular chemistry, simplifying the microencapsulation process. This innovative technology promotes energy and raw material efficiency, resulting in reduced energy consumption and waste production. Aqdot's microcapsules have potential applications across multiple sectors, including encapsulating enzymes for laundry detergents and fertilizers in agriculture. The microencapsulation market is substantial, with established uses in household and personal care products, food, and agrochemicals.

Inivata

Series B in 2019
Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. By utilizing its TAm-Seq technology, Inivata enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through a simple blood sample. This non-invasive method, known as liquid biopsy, represents a significant advancement in cancer diagnostics, allowing for improved detection, monitoring, and treatment decision-making. Inivata has also formed a strategic collaboration with NeoGenomics, Inc. to further strengthen its capabilities in this field.

AccelerComm

Seed Round in 2019
AccelerComm Ltd is a semiconductor IP-core company based in Southampton, United Kingdom, specializing in Forward Error Correction (FEC) solutions for wireless communications. Established in 2016, the company develops innovative error correction decoders designed for various markets, including mobile handsets, base stations, and satellite communications. Its product offerings include Polar, Turbo Decoder, and LDPC encoding/decoding chains, which are compliant with 3GPP standards. AccelerComm's technology addresses performance bottlenecks in next-generation wireless communication by enhancing the error correction processes necessary to mitigate the impacts of noise, interference, and poor signal strength. By providing cost-effective and high-performance solutions, AccelerComm enables clients to optimize their digital communication systems.

C-capture

Venture Round in 2019
C-Capture Ltd utilise their extensive knowledge of CO2 (carbon dioxide) based chemistry and engineering, to develop a bottom-up approach to designing solvent systems for the removal of CO2 from gas streams. CO2 is considered to be a ‘greenhouse gas’ and its release into the atmosphere is one of the leading contributors to global warming.

Featurespace

Venture Round in 2019
Featurespace is the world-leader in Adaptive Behavioural Analytics and creator of the ARIC™ platform, a machine learning software system developed out of the University of Cambridge. The ARIC™ platform uses anomaly detection to analyse complex behavioural data in real time, spotting anomalies to block new fraud attacks as they occur. At the same time, Featurespace recognises genuine customers without blocking their activity. ARIC™ reduces the number of genuine transactions incorrectly identified as fraud by over 70%, enabling businesses to accept more revenue. Head quartered in Cambridge, UK, and Atlanta, GA, U.S. Featurespace has deployed the ARIC™ platform to organisations that have services or products deployed in over 180 countries. Customers include Betfair, Vocalink/Zapp, Worldpay, and TSYS, the largest third-party processor of Visa® and MasterCard® credit cards in the U.S.

AudioScenic

Seed Round in 2019
AudioScenic Limited, established in 2017 and headquartered in Southampton, United Kingdom, specializes in 3D audio technology that enhances the listening experience across various sectors, including cinema, gaming, virtual reality, and automotive industries. The company utilizes advanced head-tracking and small arrays of speakers to deliver controlled sound beams directly to the listener's ears, creating a virtual headphone effect. This technology allows for a personalized and immersive audio experience without the need for traditional headphones or extensive loudspeaker setups. By simulating sounds positioned in 3D space, AudioScenic's solutions eliminate the limitations of conventional audio systems, providing a natural and authentic sound environment. The company's proprietary Virtua 3D Engine facilitates the implementation of its audio technology across different platforms, ensuring compatibility and optimization for various applications. AudioScenic collaborates closely with partners and customers to develop tailored acoustic designs for a range of products, enhancing the overall audio experience in both private and public settings.

import.io

Series B in 2018
Import.io Ltd is a SaaS company that specializes in Web Data Integration, enabling users to transform extensive web data into structured, machine-readable formats. Founded in 2012 and headquartered in London, with an additional office in Los Gatos, California, the company offers a suite of products including Import.io Extract for automated web extraction, Import.io Insights for data monitoring and visualization, Import.io API for system integration, and Import.io Transform for data formatting. Its solutions support various applications such as competitor price monitoring, MAP compliance, product matching, and customer sentiment analysis. Import.io serves over 850 clients by providing high-quality web data from millions of online sources, thereby enhancing business insights and competitive advantages.

WaveOptics

Series C in 2018
WaveOptics, Ltd. specializes in the design and manufacture of augmented reality display technology, focusing on optical waveguides for wearable devices. The company offers features such as binocular displays, high field-of-view, and full RGB color in lightweight designs. Founded in 2014 and based in Abingdon-on-Thames, United Kingdom, WaveOptics has established strategic partnerships with companies like Compal, Wistron, and Plessey to enhance its product offerings. The company aims to be a pivotal supplier of optical components for the growing augmented reality market.

Genomics

Series B in 2018
Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Ultraleap

Series C in 2018
Ultraleap is a leader in mid-air haptic technology and 3D hand tracking, specializing in creating tactile feedback through ultrasound. This innovative technology allows users to experience touch sensations in mid-air, enabling interactions with virtual objects, touchless buttons, and mid-air gestures without the need for physical contact. The company offers a range of products, including the Evaluation Kit, which features ultrasonic transducers and a software development kit for programming haptic sensations, and the TOUCH Development Kit, designed for creating tactile feedback in free space. Ultraleap’s technology finds applications in various sectors, including virtual reality, gaming, automotive, medical, and advertising. Established in 2013, the company operates from its headquarters in Bristol, United Kingdom, and maintains an additional office in Mountain View, California.

IBEX Innovations

Venture Round in 2018
IBEX Innovations Limited specializes in the development and commercialization of advanced X-ray detector technology that enhances material analysis capabilities. The company's proprietary multi absorption plate (MAP) technology integrates with standard X-ray detectors, enabling high sensitivity material classification while maintaining key performance characteristics such as speed and spatial resolution. This innovative solution is applicable across various sectors, including medical imaging, electronics, food safety, and security. Founded in 2010 by Dr. Gary Gibson and based in Sedgefield, United Kingdom, IBEX has rapidly evolved from its initial concept to a recognized provider of engineered solutions. The company collaborates with academic and healthcare institutions, including Durham University and NHS trusts, to validate and advance its technology. IBEX Innovations has received support from venture capital firms and grants from InnovateUK and the European Commission to foster its growth and development.

Yoyo

Series C in 2018
Yoyo Wallet Limited is a mobile wallet provider based in London, United Kingdom, founded in 2013. The company offers a digital payment platform that facilitates customer transactions through smartphones, allowing users to pay for goods while simultaneously collecting loyalty rewards. Yoyo Wallet serves a variety of clients including retailers, universities, and corporate locations across the UK. The platform processes over 150,000 monthly in-store transactions and features a marketing component that enhances digital customer engagement. By leveraging purchasing patterns, Yoyo enables retailers to deliver personalized rewards and offers, transforming anonymous shoppers into identifiable customers. This approach helps retailers better target their audience and improve customer loyalty. Yoyo Wallet was previously known as JustYoyo Limited until its name change in April 2015.

Garrison

Series B in 2018
Garrison Technology Limited develops technologies for enterprise cybersecurity needs. The company was incorporated in 2014 and is based in London, United Kingdom. It aims to serve the growing enterprise market with its anti-malware product. It wants to address the large and growing enterprise cyber security market. The company has pioneered in an anti-malware product that efficiently sidesteps the highest impact cyber threats to modern organizations, i.e. internet-borne targeted attacks. Due to Garrison’s unique technology, a previously inconceivable brand of ultra-secure internet connectivity, user experience, and enterprise scalability can be achieved.

Oxa

Venture Round in 2018
Oxbotica is developing the next generation of autonomous vehicles - creating the software that makes them go. Using the latest in computer vision and machine learning, their systems learn from their environment and share experiences with each other, so that they're getting smarter all the time. The system uses a complement of sensors and algorithms to identify and track pedestrians, cars and other obstacles in the environment.

Genomics

Series B in 2018
Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Dukosi

Venture Round in 2018
Dukosi Ltd designs, develops, and manufactures battery management systems for automotive industry. It offers cell sensor products for hybrid, plug-in hybrid, and electric automotive vehicles; mobility vehicles; and smart grids. The company’s products enable monitoring the health of individual battery cells. Dukosi Ltd was founded in 2003 and is based in Edinburgh, United Kingdom.

Artios

Series B in 2018
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.

Spirea Ltd.

Pre Seed Round in 2018
Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

Carisma Therapeutics

Series A in 2018
Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.

Silicon MicroGravity

Venture Round in 2018
Silicon Microgravity Limited, founded in 2014 and based in Cambridge, United Kingdom, specializes in developing advanced sensor devices for the oil and gas industry. Originating as a spin-out from Cambridge University, the company’s technology enables high-sensitivity gravity data recording and ultra-low frequency seismic data analysis, significantly enhancing the management of oil and gas reservoirs. Developed in collaboration with BP and supported by Innovate UK, its microelectromechanical system sensors allow for precise measurement of densities deep within reservoirs from boreholes. Additionally, the technology has applications in navigation, guidance, and stabilization for various commercial, industrial, and military uses. With its innovative approach, Silicon Microgravity aims to improve reservoir surveillance and operational efficiencies while addressing social, safety, and environmental objectives.

Lorem Therapeutics

Seed Round in 2018
Lorem Therapeutics is focusing on development early stage therapeutics in the phase between initial drug discovery and when a treatment begins review by the FDA for status as an Investigational New Drug. The company will use the funding “to accelerate and enhance our drug discovery efforts around critical cancer indications,” Slusher said in a statement.

Crescendo Biologics

Series B in 2018
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.

Enterprise Therapeutics

Series B in 2018
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

OxSyBio

Series A in 2018
OxSyBio Ltd. develops 3D printing techniques to produce tissue-like and functional tissues for medical research and clinical applications. It develops printing tissue-like materials comprised of 3-dimensional networks of lipid monolayer aqueous droplets that are used for conducting electrical signals along pre-defined pathways, and self-folding to form complex geometries. The tissues can be used in the clinic for organ repair or replacement. The company was founded in 2014 and is based in London, United Kingdom.

Econic Technologies

Venture Round in 2018
Econic Technologies Ltd. is a chemical technology company based in Macclesfield, United Kingdom, that specializes in developing novel catalysts and processes to convert waste carbon dioxide into valuable polymers and polyurethanes. Founded in 2011, the company focuses on producing polyols and surfactants that are utilized across various industries, including construction, automotive, furniture, and apparel. Their innovative approach allows for the creation of high-performance products, such as foams, coatings, sealants, and adhesives, by reacting carbon dioxide with conventional epoxides. This not only reduces dependence on fossil fuels but also transforms a harmful greenhouse gas into economically and environmentally beneficial materials. The company operates from a state-of-the-art facility at Alderley Park, where a skilled team of scientists and engineers continues to advance its patented catalyst technologies, aiming to enhance sustainability in polymer manufacturing while delivering tangible benefits to the market.

Ditto

Venture Round in 2018
Ditto AI Ltd is a Manchester-based company specializing in the development of an artificial intelligence platform tailored for enterprises. By leveraging intelligent systems and emerging technologies, Ditto aims to enhance workplace automation. The company employs a systematic approach to capture and encapsulate human expertise and the intricate processes involved in decision-making. This focus on creating reliable methodologies positions Ditto as a leader in the field of AI-driven enterprise solutions.

Arkivum

Series E in 2018
Arkivum delivers software, services and domain expertise for long term data management and digital preservation globally. We serve organisations around the world in data intensive and regulated markets. We make your long term data secure, accessible and usable for as long as you need it, providing assurance your data is where you need it, when you need it. Our domain expertise means we can guarantee 100% data integrity and best practice guidance for dealing with new compliance requirements as they are introduced. Our vendor neutral technology and no data lock-in means your data lives where you want it to and you own your data at all times. Arkivum delivers complete confidence in preserving, meeting complex compliance and regulatory requirements and creating business value from your data. Bringing your archived data to life.

Oxehealth

Venture Round in 2017
Oxehealth Ltd. is a technology company based in Oxford, United Kingdom, specializing in non-contact vital signs monitoring solutions for various sectors, including healthcare, fitness, automotive, and security. Founded in 2012, Oxehealth has developed the Oxecam software, which utilizes a digital video camera to remotely measure vital signs such as heart rate, respiratory rate, and blood oxygenation without physical contact. This innovative technology is particularly beneficial for monitoring elderly and vulnerable individuals in settings where staff presence may be limited. Oxehealth's Digital Care Assistant generates alerts regarding risky activities and provides objective data on patient activity and vital signs, enhancing care planning and allowing caregivers to focus on hands-on support. The company has achieved a world-first certification for its software as a medical device, demonstrating its commitment to transforming care environments. Oxehealth's proprietary algorithms leverage deep learning and computer vision to deliver accurate monitoring, making it a valuable tool in mental health, prison, and acute care settings.

Navenio

Seed Round in 2017
Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice. The company was founded in 2015 and is headquartered in Oxford, England.

Quantum Motion

Seed Round in 2017
Quantum Motion Technologies Limited is focused on developing a universal quantum computer utilizing silicon-based technology and CMOS-compatible processes. Founded in 2017 and based in Leeds, United Kingdom, the company aims to create scalable quantum computing architectures that address issues such as fault tolerance and qubit redundancy. Its technology is designed to enhance qubit density, allowing for the construction of large-scale quantum systems capable of solving complex problems in various fields, including chemistry, medicine, and artificial intelligence. By leveraging advanced architectural approaches, Quantum Motion Technologies seeks to advance the quantum technology sector and provide solutions that reduce errors and overcome critical challenges in quantum information processing.

Kudo Insurance

Venture Round in 2017
Kudo Insurance is a mobile application designed to enhance the car insurance purchasing experience by evaluating driving behavior through telematics. Launched in 2017, the app gathers data on users' driving habits and assigns an individual score, which users can share with insurance providers to secure better quotes and potential discounts. The application requires users to complete a driving assessment, rewarding them with Kudo Koins that can be redeemed for various goods or entries into cash prize draws. By providing a platform that emphasizes transparency and offers drivers a means to demonstrate their skills, Kudo Insurance aims to empower consumers to obtain more favorable insurance options while also serving as potential evidence in the event of an accident.

Touchstone Innovations

Acquisition in 2017
Touchstone Innovations create, build and invest in pioneering technology companies and licensing opportunities developed from outstanding scientific research focusing on the ‘Golden Triangle’ of London, Cambridge and Oxford. Their robust strategy and fully integrated business model, proven over many years, begins with original idea and extends through intellectual property (IP) protection, company formation, seed funding, incubation, scale-up and supportive investment. This provides us with a unique insight into leveraging early-stage research and turning it into substantial, high-quality, well-managed and well-funded commercial businesses. They help scientists and entrepreneurs to commercialise their idea by protecting and licensing intellectual property, leading the formation of new companies, recruiting high-calibre management teams and providing and supporting investment. They provide continuity of funding from start-up to scale-up, with initial investments from seed stage onwards. They remain an active investor throughout the lifetime of their portfolio companies, with the majority of their investment each year going into businesses they have lived with and understood for some time. This strategy substantially de-risks investment scale-up in their portfolio companies. Touchstone Innovations is at the forefront of UK early-stage technology investment. Alongside their co-investors they have leveraged over £1.5 billion to help drive high technology innovation in the UK.

Ionix Advanced Technologies

Venture Round in 2017
Ionix Advanced Technologies Ltd. specializes in the development and supply of high-performance piezoelectric devices and materials designed for high-temperature applications. Founded in 2011 and based in Leeds, United Kingdom, the company offers a diverse range of products, including sensors, actuators, and transducer devices that utilize its advanced piezoelectric materials. These devices are engineered to operate effectively in extreme environments, making them suitable for various industries such as aerospace, oil and gas, nuclear power, automotive, and non-destructive testing (NDT). Ionix's technology aims to reduce energy and operating costs while enhancing reliability and safety, particularly in applications requiring continuous operation under challenging conditions, including high temperatures and ionizing radiation.

Inductosense

Series A in 2017
Inductosense Ltd specializes in the manufacture of wireless, battery-free sensors designed for the detection of cracks, corrosion, and defects in various structures and products. Founded in 2015 and based in Bristol, United Kingdom, the company offers innovative solutions such as the WAND Evaluation System, which includes a handheld measurement probe and multiple sensors for measuring structural thickness. Their technology enables sensors to be permanently affixed to surfaces or embedded within materials, allowing for inspections beneath coatings, insulation, or repairs. Additionally, Inductosense provides TRND systems for monitoring internal corrosion and erosion in pipework and vessels. The sensors operate passively, receiving power and transmitting data through non-contact inductive coupling, facilitating fast and repeatable inspections while enabling clients to trend data over time.

Zeetta Networks

Seed Round in 2017
Zeetta Networks Limited specializes in developing and marketing open networking solutions that leverage software-defined networking (SDN) and network virtualization technologies. Established in 2015 as a spin-out from the High-Performance Networks Group of Bristol University, the company offers NetOS, a network operating system designed for heterogeneous networks. NetOS facilitates the plug-and-play management of diverse network devices and supports the creation of virtual network slices for various applications, including ultra-HD video distribution and Internet of Things deployments. The platform also incorporates a Virtualization Engine, allowing for the efficient sharing of network resources while ensuring guaranteed Quality of Service for users. In addition to its core software solutions, Zeetta Networks provides integration, support, and training services, catering to network operators, enterprises, original equipment manufacturers, and data centers. The company has engaged with major industry players, highlighting its strong market presence and innovative capabilities.

Eight19

Venture Round in 2017
Eight19 Limited, based in Cambridge, United Kingdom, specializes in the development and manufacturing of organic photovoltaics (OPVs) for lightweight solar panels. Founded in 2010, the company focuses on energy harvesting solutions for indoor, outdoor, and off-grid applications. Its OPV modules are designed for use in wireless devices, retail environments, and portable electronics, benefiting from attributes such as flexibility, thinness, and robustness. Eight19 employs industry-standard roll-to-roll processes and solution-based organic materials, allowing for a cost-effective scaling of its technology to meet market demands. The company also offers integrated demonstration units that include Bluetooth-connected temperature and light sensors, showcasing the versatility of its products in various applications.

Zilico

Venture Round in 2017
Zilico Limited is a Manchester-based company focused on developing diagnostic devices aimed at improving cancer detection, particularly cervical cancer. Utilizing electrical impedance spectroscopy technology, Zilico's flagship product, ZedScan, operates alongside colposcopy to provide real-time, objective assessments of cervical epithelial tissue. This technology addresses the limitations of traditional diagnostic methods, which often involve subjective interpretations. Zilico is actively working on two applications: one targeting the referral market and another aimed at the screening market, both designed to enhance diagnostic accuracy and reduce the subjectivity associated with current practices. Since its founding in 2006, Zilico has aimed to deliver significant health economic benefits and improve cancer screening programs. The company was previously known as Aperio Diagnostics Limited before rebranding in 2008.

Carisma Therapeutics

Seed Round in 2017
Carisma Therapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative cellular immunotherapies for the treatment of solid tumors. Founded in 2016, the company specializes in engineering chimeric antigen receptor (CAR) macrophages and monocytes, which are types of white blood cells that play a crucial role in the immune response. By harnessing advances in macrophage biology and adoptive cell transfer, Carisma aims to enhance cancer therapies, allowing for more effective treatment options for patients with solid tumors. The company is in the clinical stage of development, working to translate its proprietary technology into transformative therapies for various serious diseases.
Creavo Medical Technologies Ltd. is a UK-based medical device company focused on developing innovative imaging technologies for acute medical settings. Established in 2014, the company was founded by a team of clinical, research, and business experts to commercialize technology created by Professor Ben Varcoe. Creavo offers a portable, battery-powered medical device designed for the detection of heart-related issues, enhancing diagnostic capabilities in urgent care environments. The company operates facilities in Leeds and Coventry, aiming to improve patient outcomes through advanced diagnostic solutions.

Alesi Surgical

Venture Round in 2017
Alesi Surgical Ltd. specializes in developing and commercializing laparoscopic surgical smoke handling systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy, the company has a strong connection to experienced surgeons and trainers, enabling it to identify and address challenges in surgical techniques. Alesi Surgical distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia. Established in Cardiff, United Kingdom, the company was previously known as Asalus Medical Instruments Limited and has been operational since 2007.

Ultraleap

Series B in 2017
Ultraleap is a leader in mid-air haptic technology and 3D hand tracking, specializing in creating tactile feedback through ultrasound. This innovative technology allows users to experience touch sensations in mid-air, enabling interactions with virtual objects, touchless buttons, and mid-air gestures without the need for physical contact. The company offers a range of products, including the Evaluation Kit, which features ultrasonic transducers and a software development kit for programming haptic sensations, and the TOUCH Development Kit, designed for creating tactile feedback in free space. Ultraleap’s technology finds applications in various sectors, including virtual reality, gaming, automotive, medical, and advertising. Established in 2013, the company operates from its headquarters in Bristol, United Kingdom, and maintains an additional office in Mountain View, California.

Saw DX

Venture Round in 2017
SAW DX Ltd, a technology development company, designs and manufactures point of care (POC) diagnostic devices. Its portfolio includes development of POC board and wires prototype for use in diagnosis of sexually transmitted infections; POC demonstrator reader and disposable cartridge for use with existing diagnostic assays for tuberculosis (including latent TB); and a platform to enrich parasites and perform cell lysis and molecular detection on low-cost disposable chips. The company serves life sciences and diagnostics companies. SAW DX Ltd was incorporated in 2013 and is headquartered in Glasgow, United Kingdom.

Refract

Seed Round in 2017
Refract Software Ltd, founded in 2015 and based in Stockport, United Kingdom, specializes in developing sales coaching software that enhances the effectiveness of sales conversations. The company offers a conversation intelligence and video coaching platform that captures critical moments from various interactions, such as calls and meetings, to provide actionable insights for sales managers. By utilizing artificial intelligence, Refract identifies key phrases and behaviors that correlate with successful outcomes, allowing teams to learn from both mistakes and successes. The platform includes features such as call recording, searchable libraries of best practices, and seamless integrations with various customer relationship management systems. Refract serves a diverse range of clients, from small teams to large organizations, all focused on improving their sales processes and outcomes through effective coaching.

Dukosi

Series A in 2017
Dukosi Ltd designs, develops, and manufactures battery management systems for automotive industry. It offers cell sensor products for hybrid, plug-in hybrid, and electric automotive vehicles; mobility vehicles; and smart grids. The company’s products enable monitoring the health of individual battery cells. Dukosi Ltd was founded in 2003 and is based in Edinburgh, United Kingdom.

Microbiotica

Seed Round in 2016
Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.

Parkwalk Advisors

Acquisition in 2016
Parkwalk Advisors Ltd is a London-based venture capital firm established in 2009, specializing in investments in growth capital and spin-outs from UK universities and research-intensive institutions. The firm focuses on early and growth-stage companies across various sectors, including healthcare, energy, technology, artificial intelligence, life sciences, and advanced materials. Parkwalk typically invests between £250,000 and £10 million in unquoted companies with intellectual property backing, aiming to generate capital gains for investors while benefiting from the UK government's tax relief initiatives. The firm seeks opportunities primarily within the UK, particularly in Cambridge and its surrounding areas, leveraging extensive networks developed over many years to access high-quality deal flow. In 2017, Parkwalk became a subsidiary of IP Group Plc, enhancing its capabilities in intellectual property commercialization and expanding its investment reach.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.